CARLOS VIANA POYARES JARDIM

Índice h a partir de 2011
16
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Autor e Coautores FMUSP-HC Normalizados: CARLOS VIANA POYARES JARDIM × Tipo de produção: bookPart ×

Resultados de Busca

Agora exibindo 1 - 8 de 8
  • bookPart
    Biomarkers in Pulmonary Arterial Hypertension
    (2012) SOUZA, Rogerio; HOETTE, Susana; DIAS, Bruno; JARDIM, Carlos
    Together with the improvement of pulmonary arterial hypertension (PAH) management arises the need for adequate surrogate markers for treatment decision and follow-up. In this setting, biomarkers play a definitive role. A number of biomarkers addressing specific features of the different pathophysiological mechanisms of PAH, with the ability to describe disease severity and prognosis, have been described. This chapter reviews the characteristics of the different existing biomarkers as the rationale for their integration as the next step for the evaluation of PAH patients. Copyright (C) 2012 S. Karger AG, Basel
  • bookPart
    Doenças da Circulação Pulmonar
    (2016) BARBAS, Carmen Sílvia Valente; BORGES, Eduardo da Rosa; ANTUNES, Telma; TAVARES, Marcos Soares; DOURADO, Leticia Kawano; AB'SABER, Alexandre Muxfeldt; CAPELOZZI, Vera; FONSECA, Guilherme Henrique Hencklain; JARDIM, Carlos Viana Poyares; SOUZA, Rogério
  • bookPart
    Hipertensão arterial pulmonar
    (2016) HOVNANIAN, André Luiz Dresler; JARDIM, Carlos; SOUZA, Rogério
  • bookPart
    Schistosomiasis and Pulmonary Hypertension
    (2012) FERNANDES, Caio Julio Cesar; JARDIM, Carlos; HOVNANIAN, Andre; HOETTE, Susana; MORINAGA, Luciana Kato; SOUZA, Rogerio
    Schistosomiasis is the third leading parasitic disease in the world. It is present in 74 countries, infecting 200 million people. Each year 280,000 patients die because of the disease. One of its most severe complications is pulmonary arterial hypertension (PAH). Previous studies have shown that 5% of patients with hepatosplenic schistosomiasis develop PAH. It is believed today that the most prevalent cause worldwide of PAH is schistosomiasis. Specifics about schistosomiasis-associated PAH including epidemiological data, mechanisms of the disease, clinical and hemodynamic features, and modalities of treatment will be reviewed in this chapter. Copyright (C) 2012 S. Karger AG, Basel
  • bookPart
    Hipertensão arterial pulmonar
    (2014) HOVNANIAN, André Luiz Dresler; JARDIM, Carlos; SOUZA, Rogério
  • bookPart
    Hipertensão Arterial Pulmonar
    (2019) HOVNANIAN, André Luiz Dresler; JARDIM, Carlos; SOUZA, Rogério
  • bookPart
    Hipertensão Pumonar
    (2016) SOUZA, Rogério; JARDIM, Carlos Viana Poyares; FERNANDES, Caio Júlio César dos Santos; FONSECA, Guilherme Henrique Hencklain; TERRA FILHO, Mário
  • bookPart
    Hipertensão arterial pulmonar
    (2016) ALVES JR., José Leonidas; JARDIM, Carlos; SOUZA, Rogério